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Evolution of biological agents: how established drugs
can become less safe
Changes to the manufacturing of biological agents can lead to drugs with different components from
the original medicine tested in clinical trials, challenging assumptions about safety, say David Hunt
and colleagues
Nicole Casadevall professor of haematology 1, Oliver Flossmann consultant nephrologist 2, David
Hunt honorary consultant neurologist and Wellcome Trust intermediate clinical fellow 3
1Hôpital Sainte-Antoine, Paris, France; 2Royal Berkshire Hospital, Reading, UK; 3Anne Rowling Clinic, Centre for Clinical Brain Sciences, University
of Edinburgh, UK
Biological drugs, such as recombinant proteins and monoclonal
antibodies, have revolutionised the treatment of many diseases.1 2
By definition, these agents are complex molecules produced in
living cells, requiring multistep manufacturing processes such
as cell culture, purification, stabilisation, and packaging.3
Biological drugs (or “biologicals”) differ from small molecule
drugs in that they are highly sensitive to changes in
manufacturing. As a result, the safety profile of established
biologicals can alter over time, posing a major challenge to the
safety frameworks for such drugs.
Biologicals change over time
Changes to the manufacturing of biologicals are surprisingly
common, although healthcare professionals and patients are
often unaware of them. For example, infliximab has undergone
more than 35 alterations in its clinical lifetime of nearly 20
years.4 Most of these changes will have been relatively minor,
and the manufacturer will have demonstrated to the regulator
that the biological was unchanged at a physicochemical level.3
But not all changes are trivial, and some are introduced with
the explicit intention of improving clinical parameters. Even if
clinical trials are required after substantial alterations, they are
typically short and rarely powered to detect adverse events that
are uncommon or rare and serious.
“Biological evolution” describes how sequential manufacturing
changes can cause the properties of a biological to diverge from
the original (fig 1⇓).5 For example, a recombinant protein might
undergo sequential alterations to three key components—the
active biological substance, the stabiliser, and the
packaging—leading to a biological drug where all the main
components have been changed. So does the drug retain the
safety and efficacy profile of the original? Whether an object
retains it fundamental properties after all its components have
been sequentially replaced has puzzled both ancient and modern
philosophers (box 1). Today it poses an important practical
question for drug safety.
This question challenges a dogma of drug safety: namely that
older, established biologicals, which have been in widespread
use for decades, have stronger evidence for their safety than
their newer counterparts. This narrative is reinforced by the
marketing materials of established brands, which promote a
reassuring message of “decades of use” or “millions of patients
treated.” The need for critical evaluation of this message has
been heightened by the introduction of biosimilar agents, first
in Europe and more recently in the US.2 Biosimilars are new
drugs that are similar to licensed biological agents, with no
clinically meaningful differences in quality, efficacy, or safety.4
The primary safety concern with biosimilars is that they are
made by new manufacturing processes that have been tested in
limited clinical trials. Their safety profiles are, therefore,
perceived to be less well defined than their established
counterparts.4 But problems associated with limited testing of
new manufacturing methods can equally affect older brands,
despite reassuring marketing.
Biological evolution can improve or
worsen safety
Changes to biologicals are often driven by a manufacturer’s
intention to improve an established biological drug, perhaps to
be less immunogenic, better tolerated, or safer.6-9 These
improved parameters can be readily assessed in short trials,
comprising a few hundred patients or fewer.3-10 Such trials can
provide reliable safety data about the short term clinical
performance of evolved biological drugs but are not usually
able to detect changes in long term safety or efficacy.11 If the
biological has diverged from the original in a beneficial
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Box 1: Trigger’s broom and Theseus’ ship
“I’ve maintained this old broom for 20 years. It’s had 17 new heads and 14 new handles in its time.”—Trigger in Only Fools and Horses
“The ship wherein Theseus returned was preserved by the Athenians. For they took away the old planks as they decayed, putting in new
and stronger timber in their place. This ship became a standing example among the philosophers . . . one side holding that the ship remained
the same, and the other contending that it was not the same.”
The Life of Theseus, Plutarch
parameter, it may also have diverged in a detrimental
parameter—and this may be more difficult to detect.
Recombinant erythropoietin provides the first well documented
example of how the safety profile of an evolved biological can
deteriorate compared with the original.8 This recombinant
protein is widely used to treat anaemia and can cause pure red
cell aplasia, a serious adverse event mediated by neutralising
antibodies directed against erythropoietin.12 13 In the first decade
of postmarketing use, pure red cell aplasia was reported in only
three patients worldwide who received recombinant
erythropoietin. However, a sustained increase in incidence was
subsequently observed in Europe, where an evolved preparation
of erythropoietin-α had been introduced.8 The preparation had
undergone several sequential changes, in particular to the drug
stabiliser and packaging, resulting in a change to protein
immunogenicity. Although the exact cause was not definitively
identified, concerted efforts to alter drug storage, injection, and
manufacturing led to a drop in incidence of pure red cell aplasia.8
A natural experiment of regulation
Regulatory authorities have differed in their approaches to the
approval of evolved biologicals, setting the conditions for a
potentially informative, if unintentional, natural experiment.
Recombinant interferon beta has been used for the treatment of
multiple sclerosis since 1998, and, although of only modest
efficacy, it is considered to be well tolerated with a strong safety
record.14-16 As it entered its second decade of widespread use,
the European Medicines Agency approved an evolved interferon
beta preparation for use, whereas the US Food and Drug
Administration did not.10 The product had undergone two
sequential changes—a new cell clone was introduced in 2003,
and the stabiliser was changed to remove human serum
components in 2007.10 The new product had a better short term
safety profile than the original, in particular a lower
immunogenicity profile.6 However, an unexpectedly high
number of cases of renal failure caused by thrombotic
microangiopathy were identified in Europe in association with
the evolved product (fig 2⇓).17 18
Thrombotic microangiopathy is a disease of small blood vessels
that can cause fulminant organ failure. It is caused by a direct
toxic effect of interferon beta protein and is exceptionally rare
as a spontaneous disease.19 20 It had not been identified as a
problem with the original formulation of interferon beta, with
no cases in extensive clinical trials covering many thousands
of patient years and only three cases reported worldwide in
almost a decade of postmarketing use.17 By contrast, a strong,
specific, and sustained signal of disproportionate reporting for
thrombotic microangiopathy was seen in countries where the
evolved preparation had been introduced (fig 2⇓).17-21
Flying under the radar?
Subsequent efforts to quantify this safety signal in populations
in which efforts have been made to actively identify cases
indicate that thrombotic microangiopathy can occur at an
incidence of ~1 in 1000 patient years in patients with multiple
sclerosis treated with evolved interferon beta and is associated
with a 10-20% mortality rate.17-22 When serious adverse events
of a similar magnitude have been detected early in pivotal
clinical trials for other drugs for multiple sclerosis,
manufacturers and regulators have responded quickly and
vigorously, sometimes with temporary market suspension, to
enable development of a robust risk mitigation programme.23
By contrast, warnings about thrombotic microangiopathy
associated with interferon beta have been incremental and of
lower profile, with little in the way of active risk
management.17 20 This raises the question of whether serious
adverse events associated with an evolved biological might
trigger a less robust safety signal than the original.
Uncommon but serious adverse events are likely to be detected
in the extensive clinical trials of an original biological product,
which can span many thousand patient years. However, the
much shorter trials of evolved products, with only a few hundred
patient years of exposure, may not detect a single case.8-11 This
difference is crucial because even a single case in clinical trials
can trigger further dedicated longitudinal study of the adverse
event to accurately quantify risk.24 If this opportunity is missed,
then detecting and quantifying safety signals relies on
spontaneous reporting, where data from the evolved product
are potentially subject to a “double dilution” effect.25 Firstly,
only a small fraction of the true number of cases are reported
because adverse event data are no longer actively collected.25
Then the safety data from the evolved product may be further
diluted by being pooled with extensive datasets from the original
formulation. This is particularly concerning because adverse
events associated with evolved biologicals may emerge at a
time when safety data from the evolved product are dwarfed by
that of the original (fig 3⇓).
Optimising pharmacovigilance
Unbiased and proactive reporting
Spontaneous reporting is crucial for the generation of safety
signals, so all doctors who prescribe and monitor biologicals
should be aware of the phenomenon of biological evolution and
guard against the potentially false reassurance of “a well
established safety profile.” Doctors should not assume that
unexpected and serious risks cannot occur just because a familiar
branded biological has been used for decades. Indeed, the longer
the established safety profile, the stronger the potential diluting
effect of pre-existing data (fig 3⇓).
Direct communication between reporting clinicians, national
drug safety agencies, and scientists can have an important role
in the accurate definition of emerging drug induced syndromes.
Thrombotic microangiopathy associated with interferon beta
was recognised and reported differently between specialties;
nephrologists recognised and reported it as “haemolytic uraemic
syndrome,” cardiologists as “malignant hypertension,” and
haematologists as “thrombotic thrombocytopenic purpura.”
These observations, informed directly from the bedside,
facilitated more specific analyses of national and global safety
datasets, enabling emergent safety signals to be more clearly
defined than when broader case descriptions were used.17 22
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Vigilance for adverse event reporting should be maintained
throughout the lifetime of a drug. Healthcare professionals and
patients may need to be more aware of major manufacturing
changes, although alert systems can introduce their own
reporting biases.26 The pharmacovigilance model of spontaneous
reporting may be fundamentally limited in its sensitivity to
detect dynamic changes associated with biological evolution,
highlighting the need for additional active surveillance systems.
Biological registries
Several medical specialties recognised early the particular
challenges of safety of biologicals, starting a culture of active
surveillance led by healthcare professionals, exemplified by
biological registries.27 Although the pharmaco-epidemiology of
biological agents is becoming ever more complex, a simple
principle to evaluate risk of adverse events is to ensure accurate
measures of case ascertainment and patient exposure. Biological
registries achieve this through unbiased active reporting of
adverse events, coupled to tracking of manufacturing changes.
The British Society for Rheumatology established its biological
registry over a decade ago. It has enabled more precise mapping
of adverse events with biological agents, in particular
complications with long term exposure.28 UK neurologists opted
instead to monitor the cost effectiveness of new biologicals for
treating multiple sclerosis through a risk sharing scheme.15 29
Patients with multiple sclerosis who developed serious
complications from thrombotic microangiopathy associated
with interferon beta were being actively monitored through this
prospective cohort study, but efficacy rather than safety data
were collected. Given the continued rise in use and complexity
of biologicals, individual medical specialties should consider
the adequacy of their current frameworks.
Dedicated research
Biological evolution itself is understudied. Manufacturers and
regulators readily accept that biological evolution can improve
the short term safety profile of a drug yet are more reluctant to
accept that it might alter the long term safety profile.22 30 Some
regulators and manufacturers have questioned the validity of
strong safety signals with evolved biologicals because, by
necessity, they rely on spontaneous reporting data rather than
rigorous pharmacoepidemiological studies.22 30 The absence of
such studies is arguably the problem, hampering our
understanding of the true extent of the challenges posed by
evolved biologicals.
Notably, the examples we describe here led to meaningful
alterations in the immunogenicity of a recombinant protein. On
one hand, increased immunogenicity can cause serious adverse
events, such as pure red cell aplasia.12 13 On the other hand,
reductions in immunogenicity can increase drug bioavailability
and unmask toxic drug effects.20 31
Other key questions need to be answered: Which manufacturing
changes are most likely to alter safety profiles? Are changes
caused by a single, critical change, or the accumulation of many?
Does this phenomenon particularly affect recombinant proteins
or are monoclonal antibodies and vaccines also affected? The
answers are critical to the design of an optimal monitoring
framework, which balances cost, innovation, and safety.2
Conclusion
Biological evolution has the potential to improve or worsen the
safety profile of established biological medicines, but current
safety frameworks are more likely to emphasise short term
improvements. More research is needed to understand the
potential long term safety implications of such changes and to
see if current safety frameworks might be further improved. In
the meantime, all healthcare professionals should be aware of
the phenomenon of biological evolution while executing their
duty of drug safety reporting and should avoid complacency
when prescribing established biological agents.
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Figures
Fig 1 Evolution of biological drugs. A) Definition. B) An example.
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Fig 2 Evolution of interferon beta and reports of thrombotic microangiopathy. Reprinted with permission.17
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;357:j1707 doi: 10.1136/bmj.j1707 (Published 2017 April 27) Page 6 of 7
ANALYSIS
Fig 3 The potential for dilution of safety signals from evolved biologicals. Exposure of an evolved biological can be dwarfed
by the patient exposure of the original product. One person represents 500 patient years.
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